We have shown previously that mRNA for peroxisome proliferator-activated receptor g (PPARg) is expressed in granulosa cells and downregulated by the luteinizing hormone (LH) surge. The current studies were undertaken to test the hypothesis that LH stimulates a decrease in the expression of PPARg, as well as its activity, in granulosa cells. Ovaries were collected from immature rats 0 and 48 h after they received pregnant mares' serum gonadotropin (PMSG), and 4 and 24 h after administration of human chorionic gonadotropin (hCG), and used for protein isolation or processed for immunolocalization of PPARg. The amount of phosphorylated PPARg was measured by immunoblot analysis to determine how LH affects the phosphorylation status, and therefore the activity, of PPARg. Granulosa cells were also collected from immature rats 48 h after PMSG. Cells were cultured with LH in the absence and presence of H89 and cycloheximide to investigate the role of PKA and protein synthesis in the LH-mediated decline in mRNA for PPARg respectively. Protein corresponding to PPARg was localized to nuclei of granulosa cells 0 and 48 h after PMSG. Expression was greatly reduced by 4 h after hCG, with expression in mural granulosa cells lost before that in cumulus cells. The amount of phosphorylated PPARg did not change during the periovulatory period. Blocking PKA activity had no effect on levels of mRNA for PPARg. However, levels of mRNA for PPARg were significantly increased in cells treated with cycloheximide (P < 0.05, ANOVA followed by Tukey's HSD). These data suggest that PPARg is tightly regulated in the ovary and that its expression is the primary mechanism by which LH influences the activity of PPARg. In addition, protein synthesis may be involved in modulating levels of PPARg in granulosa cells. 
Introduction
Peroxisome proliferator-activated receptor g (PPARg) has been identified in ovarian tissue of man (Lambe & Tugwood 1996) , cattle (Sundvold et al. 1997 , Lö hrke et al. 1998 ), sheep (Froment et al. 2003 , pigs (Schoppe et al. 2002) , rats (Braissant et al. 1996 , Komar et al. 2001 ) and mice (Cui et al. 2002) . Mohan et al. (2002) reported that PPARg is also expressed in bovine oocytes. Our laboratory (Komar et al. 2001 ) and others (Lö hrke et al. 1998 , Mu et al. 2000 , Schoppe et al. 2002 , Froment et al. 2003 , Lovekamp-Swan et al. 2003 have shown that PPARg can also influence ovarian steroid production. Agonists of PPARg have been reported to modify steroid production by both follicular (Komar et al. 2001 , Schoppe et al. 2002 , Froment et al. 2003 , LovekampSwan et al. 2003 and luteal cells (Lö hrke et al. 1998 , Mu et al. 2000 .
PPARg is a member of the PPAR family of nuclear hormone receptors. This transcription factor is predominantly known for its role as an adipocyte differentiation factor (reviewed by Debril et al. 2001) . PPARg also plays a role in lipid and glucose homeostasis, inflammation, the cell cycle, and cancer (reviewed by Escher & Wahli 2000 , Berger & Moller 2002 . It plays a critical role in placental development and function, as illustrated by disrupted trophoblast differentiation and placental vascularization in mice lacking PPARg (Barak et al. 1999) .
Aside from the roles mentioned above, there are several other mechanisms by which PPARg could affect ovarian function. PPARs can directly regulate the expression of the rate-limiting enzyme involved in prostaglandin production, cyclooxygenase-2 (COX-2) (Meade et al. 1999) , and the proteolytic enzymes, MMP-3 (Yee et al. 1997) and MMP-9 (Marx et al. 1998 , 1999 , Shu et al. 2000 . PPARg can also regulate the expression of vascular endothelial growth factor (Yamakawa et al. 2000) , and could thereby affect angiogenesis, which is critical for follicular and luteal development. Genes involved with cell-cycle regulation (reviewed by Theocharis et al. 2004 ) and cell survival (Butts et al. 2004) are also regulated by PPARg.
There are various mechanisms regulating the activity of PPARg. PPARg can be ubiquinated (Hauser et al. 2000) , sumoylated (Ohshima et al. 2004 ) and nitrated (Shibuya et al. 2002) , reducing its ability to affect gene transcription. The activity of PPARg can also be modified by phosphorylation. The A/B domain in the amino-terminus of this receptor contains mitogen-activated protein kinase sites at serines 84 (Adams et al. 1997) and 112 (Hu et al. 1996) . Phosphorylation of PPARg decreases its activity (Hu et al. 1996 , Adams et al. 1997 , Reginato et al. 1998 , Camp et al. 1999 , Hsi et al. 2001 , and increases its degradation by facilitating the targeting of PPARg to the cellular ubiquitin-proteosome system (Floyd & Stephens 2002) .
Although a great deal has been learned about PPARg since its discovery over a decade ago, not much is known about the role of PPARg in the ovary. Previous work from our laboratory has shown that mRNA for PPARg is primarily localized in granulosa cells, and is downregulated in response to the luteinizing hormone (LH) surge (Komar et al. 2001) . Interestingly, cells that responded to the LH surge lost expression of mRNA for PPARg, whereas those that did not respond to the surge maintained PPARg expression (Komar & Curry 2003) .
The LH surge plays a pivotal role in the ovarian cycle. Genes essential for ovulation and luteinization are turned on by the LH surge (i.e., progesterone receptor) (Lydon et al. 1995) , whereas genes not required for these processes, or that may interfere with ovulation or luteinization, are downregulated (i.e., cyclin D2) . One mechanism that may result in amplification of the effects of the LH surge on ovarian gene expression is regulation of PPARg, and therefore PPARgregulated genes. Therefore, the following experiments were conducted to investigate the effects of the LH surge on the expression and activity of PPARg in the ovary. We tested the hypothesis that the LH surge stimulates a decrease in the amount of PPARg, as well as its activity, in periovulatory granulosa cells. Our findings show that the expression pattern of PPARg closely parallels that of its mRNA, and that protein synthesis may be involved in regulating the expression of PPARg.
Materials and Methods

Materials
Unless otherwise noted, all chemicals came from Sigma or Fisher Scientific (Pittsburgh, PA, USA). Antibodies against PPARg were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antiphosphoserine antibody was purchased from Upstate (Lake Placid, NY, USA), and the antiactin antibody was obtained from Oncogene Research Products (San Diego, CA, USA). Pregnant mares' serum gonadotropin (PMSG) and LH were purchased from the NIDDK's National Hormone and Peptide Program (Torrance, CA, USA). H89 was obtained from Alexis Biochemicals (San Diego, CA, USA).
Animals
All animal procedures were approved by Iowa State University's Animal Care and Use Committee. Animals were housed in a controlled environment with a 14:10 light: dark cycle, and had free access to food and water. Female, Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN, USA) were injected with 10 IU PMSG subcutaneously on day 23 of age. Forty-eight hours later, animals received 10 IU human chorionic gonadotropin (hCG) subcutaneously to stimulate ovulation and luteal development. Animals were killed and their ovaries collected 0 (no PMSG) and 48 h after receiving PMSG, and 4 and 24 h after hCG (n ¼ 4-5 animals/time point). Ovaries were frozen and stored at 270 8C until used for protein extraction, or fixed in 4% paraformaldehyde overnight at 4 8C. Fixed tissues were embedded in paraffin for immunohistochemical analysis.
The role of protein kinase A (PKA) and protein synthesis in the LH-mediated decline in PPARg was investigated with cultured granulosa cells collected from PMSG-primed animals. On day 23 of age, female rats received 10 IU PMSG subcutaneously. After 48 h, granulosa cells were collected as described previously (Mann et al. 1991) .
Immunohistochemistry
PPARg was immunolocalized in fixed ovarian tissues collected from rats 0 and 48 h after PMSG, and 4 and 24 h after hCG. Tissues were sectioned at 4 -5 mm, dewaxed and rehydrated. After quenching endogenous peroxidase activity in 1.5% hydrogen peroxide in methanol, tissue sections were blocked with 10% normal goat serum. The PPARg antibody (E-8; 1:100 dilution) was applied overnight at 4 8C. After rinsing, sections were incubated with a biotinylated secondary antibody (Amersham) and subsequently treated with a peroxidase/streptavidin conjugate (Vector Laboratories, Burlingame, CA, USA). The immunocomplex was detected by incubating the tissue sections with a diaminobenzidine solution (Zymed Laboratories, San Francisco, CA, USA). Normal goat serum was used in place of the anti-PPARg antibody as a control. At least nine tissue sections from each of 3 -4 animals/time point were analyzed.
Immunoprecipitation and immunoblot analysis of PPARg
Protein corresponding to PPARg was immunoprecipitated from frozen rat ovarian tissue (n ¼ 3 -4/time point). Ovaries were homogenized in RIPA buffer (1 £ phosphate buffered saline (PBS), 1% NP-40, 0.5% sodium deoxycho-late and 0.1% sodium dodecyl sulfate (SDS)) containing phenylmethylsulfonyl fluoride (100 ml/ml) and sodium orthovanadate (1 mM). The homogenate was centrifuged, and 50 ml/ml protein A agarose (Repligen, Waltham, MA, USA) were added to the supernatant. After incubation and subsequent centrifugation, the supernatant was collected and 2 mg/ml anti-PPARg antibody (H-100) was added and incubated. A volume of 50 ml protein A was added to the solution, and, after incubation, the solution was centrifuged. The supernatant was discarded and the pellet washed with RIPA buffer. The resultant pellet was resuspended in 40 ml SDS buffer (0.019 M Tris-HCl, 0.186 M glycine and 0.05% SDS).
To determine the phosphorylation status of PPARg, equal amounts of immunoprecipitate from ovarian tissue samples collected 0 and 48 h after PMSG, and 4 and 24 h after hCG were loaded onto a 10% polyacrylamide gel, separated by electrophoresis and transferred to a nitrocellulose membrane (Amersham). Membranes were blocked with 5% milk and incubated with an antiphosphoserine antibody (MPM-2; 1:500 dilution). After washing, membranes were treated with a horseradish peroxidase-labeled secondary antibody (1:1000 dilution), and the immunocomplex was visualized with an enhanced chemiluminescence (ECL) kit (Amersham). Membranes were stripped and subsequently processed for immunodetection of PPARg (E-8) to verify immunoprecipitation. Membranes were exposed to Kodak X-OMAT autoradiography film from 15 s to 5 min to ensure linearity of the signal. Films were scanned, and densitometry of the bands was conducted with AlphaEase 4.0 (Alpha Innotech, San Leandro, CA, USA).
Cell culture
Granulosa cells were cultured as previously described (Komar et al. 2001) with the following modifications. To investigate the role of PKA in the LH-mediated decline in mRNA for PPARg, granulosa cells were cultured with LH (100 ng/ml) in the presence and absence of H89 (10 or 30 mM), an inhibitor of PKA. LH and H89 were added to the cells at the time of plating. Cells were collected after 24-h culture and lysed with lysis buffer (Ambion, Austin, TX, USA). Cellular lysate was stored at 270 8C until analyzed by a direct lysate RNase protection assay. Progesterone was measured in conditioned media by RIA (Diagnostic Products, Los Angeles, CA, USA) (Komar et al. 2001) . Treatment with H89 resulted in approximately 24% and 72% decreases in basal and LH-stimulated progesterone production respectively.
Cells were also treated with cycloheximide to determine the role of protein synthesis in the LH-stimulated decrease in mRNA for PPARg. Fetal calf serum (5%) was used in the culture media in place of BSA. Cycloheximide (10 mg/ml) was added to cells at the time of plating, and LH (100 ng/ml) was administered to the cells 30 min later.
After 5-h culture, cells were collected and processed as described above.
Quantification of mRNA for PPARg
Plasmids containing cDNAs for PPARg (generously provided by Dr Walter Wahli, Université de Lausanne, Lausanne, Switzerland) and the ribosomal protein L32 (a gift from Dr O-K Park-Sarge, University of Kentucky, Lexington, KY, USA) were linearized with EcoRI. Antisense riboprobes were transcribed with Ambion's Maxiscript kit and a 32 P-UTP. Lysate ribonuclease protection assays (RPA) were carried out as described previously (Jo et al. 2002) . Briefly, granulosa cell lysates were hybridized overnight with excess radiolabeled antisense riboprobes for PPARg and L32. Protected fragments were analyzed by PAGE. Relative levels of mRNA for PPARg and L32 were quantified with a phosphor imager (Molecular Dynamics, Sunnyvale, CA, USA). The band intensity of mRNA for PPARg was normalized to the corresponding band for L32 per sample.
Statistical analysis
Differences in levels of mRNA and protein corresponding to PPARg, and the amount of phosphorylated PPARg in ovarian tissues were analyzed by ANOVA. Post-hoc comparisons were made with Tukey's HSD test. P , 0.05 denoted significant differences.
Results
Previously, we reported that mRNA for PPARg was localized primarily to granulosa cells of developing follicles, and that administration of hCG to PMSG-primed rats resulted in a significant decrease in levels of mRNA for PPARg within 4 h (Komar et al. 2001 ). In the current study, protein corresponding to PPARg was analyzed in ovarian tissue collected at defined times before and after the LH surge to determine whether the gonadotropin surge modified its expression and/or functional status.
PPARg was immunolocalized in ovarian tissue collected from immature rats 0 and 48 h after PMSG, and 4 and 24 h after hCG. PPARg was expressed almost exclusively in granulosa cells of developing follicles, and was immunolocalized to the nucleus (Fig. 1) . Expression of PPARg was relatively high in granulosa cells during follicular development (0 and 48 h after PMSG) ( Fig. 1A and B) . However, by 4 h after hCG, granulosa cells in some follicles lost expression of PPARg, while PPARg expression remained high in other follicles (Fig. 1C) . Interestingly, after the gonadotropin surge, the expression of PPARg within a follicle appeared to decline in a progressive manner. PPARg was highly expressed in some granulosa cells, but absent from others within the same follicle (indicated by arrows in Fig. 1C ). The cumulus granulosa cells appeared to retain expression of PPARg longer than mural Effects of LH on PPARg 95 granulosa cells (Fig. 1C) . By 24 h after hCG, expression of PPARg in luteal tissue was very low (Figs 1D and 2A) . Cells within the newly forming luteal tissue did express PPARg, albeit at a much lower level than what was observed in follicular cells ( Fig. 2A) .
Interestingly, in tissue collected from one animal 48 h after PMSG, the theca externa of a few follicles expressed PPARg at a high level in a relatively uniform pattern (data not shown). Aside from certain follicles in this one animal, the expression of PPARg in the theca externa of other follicles in this animal, and in the other animals studied, was inconsistent and nonuniform ( Fig. 1 ).
As mentioned above, the phosphorylation status of PPARg can influence its activity. To determine whether the LH surge influences the activity of PPARg by modifying the phosphorylation status of this transcription factor, PPARg was immunoprecipitated from ovarian tissue collected during the periovulatory period. The phosphorylation status of PPARg was determined both before and after the gonadotropin surge, and was expressed as a ratio of the amount of total PPARg in the sample. Levels of phosphorylated PPARg tended to decrease 0 -48 h after PMSG (reduced by 25%; P . 0.05), and then remained steady throughout the remainder of the periovulatory period (data not shown). The LH surge sets in motion a cascade of events that culminates in ovulation and luteinization. To begin investigating the second messenger systems involved in the LHmediated decline in the expression of PPARg in follicular cells, granulosa cells were treated with LH in conjunction with H89, an inhibitor of PKA. As seen in Fig. 3 , H89 had no effect on the basal expression of mRNA for PPARg. However, administration of LH to the cultured cells reduced levels of mRNA for PPARg by 54% compared with controls (P , 0.05) (Fig. 3) . This reduction in mRNA for PPARg in response to LH was not affected by cotreating the cells with H89 (Fig. 3B) .
The role of protein synthesis in the LH-stimulated reduction in PPARg was also investigated by treating granulosa cells in vitro with cycloheximide. As seen in the previous experiment, treating the cells with LH caused a significant decrease in levels of mRNA for PPARg (P , 0.05) (Fig. 4) . When the cells were treated with both LH and cyclohexamide, the levels of mRNA for PPARg were not different from those in control cells. Interestingly, granulosa cells treated with cyclohexamide alone had 30% more mRNA for PPARg than did controls (P , 0.05) (Fig. 4B) . 
Discussion
Data from various studies suggest that PPARg plays a critical role in normal ovarian function. Using cre/loxP technology, Cui et al. (2002) disrupted the expression of PPARg in granulosa cells, as well as B and T cells, and the mammary gland. One-third of these transgenic females were infertile, and the remaining two-thirds suffered from subfertility (Cui et al. 2002) . The authors hypothesized that the fertility problems may have been caused by disruption of PPARg in the ovary, resulting in insufficient ovarian function to support implantation. In addition, studies by Froment et al. (2003) and Swan and Chaffin (2004) have shown that endogenous PPARg is functional in granulosa cells. In these studies, granulosa cells were transiently transfected with reporter constructs whose expression was driven by peroxisome proliferator-activated receptor response elements. Both in the absence and presence of agonists for PPARg, there was an increase in reporter activity (Froment et al. 2003 , Swan & Chaffin 2004 , indicating that PPARg is functional in granulosa cells and that endogenous ligand is also present within these cells (Swan & Chaffin 2004) .
Although PPARg has been identified in ovarian cells from various species, there is a paucity of information regarding how this transcription factor is regulated in the ovary, and what genes it targets in ovarian cells. We reported previously that LH regulates the expression of mRNA for PPARg in granulosa cells of developing follicles (Komar et al. 2001 ). In the current study, we show that the expression of protein corresponding to PPARg parallels that of its mRNA. Taken together, these findings indicate that levels of both mRNA and protein corresponding to this transcription factor are tightly regulated in the ovary by LH.
Further evidence supporting tight regulation of PPARg in the ovary comes from the observed increase in basal levels of mRNA for PPARg in granulosa cells treated with cycloheximide. Blocking protein synthesis led to significant accumulation of mRNA for PPARg. This finding shows that there is rapid turnover of mRNA for PPARg in granulosa cells.
The high level of PPARg in developing follicles, both mRNA (Komar et al. 2001 ) and protein (current study), implies that this transcription factor is important in granulosa cell development and function. Since these processes depend on sequential and temporal patterns of gene expression, regulation of transcription factors would be one way to ensure that gene expression is tightly controlled. The current study demonstrates that LH decreases the expression of PPARg, but does not affect its phosphorylation status. Therefore, the activity of PPARg in ovarian cells may be regulated moreso by controlling its expression, or by modifications other than phosphorylation.
LH can stimulate various second-messenger systems, including PKA and phospholipase C (Davis et al. 1986 ). The current study shows that the decline in PPARg is not mediated by the activity of PKA. High doses of LH, such as those attained during the LH surge, are associated with the activation of phospholipase C as well as PKA (Morris & Richards 1993 , Flores et al. 1998 , and references therein). Therefore, the effect of LH on the expression of PPARg may be mediated by activation of phospholipase C. Tyrosine kinases are also activated by LH (Davis 1994) and may be involved in regulating expression of PPARg. Studies are currently underway in our laboratory to determine the intracellular signaling mechanisms behind the LH-induced decline in expression of PPARg.
The observed progression in the decline of PPARg in periovulatory granulosa cells, mural cells losing expression before the cumulus cells, is most likely the result of a direct effect of LH. Because cumulus cells lack LH receptors (Peng et al. 1991) , they do not respond directly to changes initiated by the LH surge, but rather indirectly via factors produced by neighboring mural granulosa cells.
Some effects of the LH surge are mediated by the progesterone receptor (Lydon et al. 1995 , Robker et al. 2000 , Shao et al. 2003 . However, it is unlikely that the progesterone receptor plays a role in the effect of LH on the expression of PPARg. Blocking activation of the progesterone receptor in cultured rat granulosa cells by treating them with ZK98299 did not affect the LH-mediated decline in PPARg (unpublished data, M Jo and C Komar). In addition, there is an inverse relationship between the LH-mediated decrease in PPARg, and increase in the progesterone receptor; PPARg declines by 4 h after hCG (Komar et al. 2001, current study), whereas the progesterone receptor increases 3 -6 h after hCG (Park & Mayo 1991 , Shao et al. 2003 .
The LH-mediated reduction in PPARg may be one mechanism by which the gonadotropin surge effects changes in gene transcription allowing for ovulation, and luteinization of follicular cells. The rapid decline in PPARg in response to the LH surge, and low level of expression in developing luteal cells, indicates that genes transcriptionally regulated by PPARg are not important agents in, and in fact may interfere with, ovulation and luteinization. For example, the downregulation of aromatase and cyclin D2, and upregulation of COX-2 in response to the LH surge, is important for the follicular/luteal phase shift and ovulation (reviewed by Richards 1994 . Interestingly, these genes have been shown to be regulated by PPARg in nonovarian tissues and cells (Meade et al. 1999 , Laurora et al. 2003 , Fan et al. 2005 .
In cultured granulosa cells from PMSG-primed immature rats (Lovekamp-Swan et al. 2003) and human granulosa-lutein cells (Mu et al. 2000) , activation of PPARg reduced the expression of aromatase. The inhibitory effect of PPARg on aromatase expression is through disrupting the interaction of NF-kB with the aromatase promoter II (Fan et al. 2005) . Within 6 h of the gonadotropin surge, there is a significant decline in the expression of aromatase in granulosa cells (Hickey et al. 1988) . We reported previously that there was no correlation between the expression of mRNAs for PPARg and aromatase in granulosa cells during folliculogenesis or the periovulatory period (Komar & Curry 2003) . These observations, taken together with the fact that PPARg is expressed in granulosa cells coincidently with estradiol production, suggest that this transcription factor may not inhibit aromatase in the ovary under normal, physiologic conditions. Cyclin D2 has a similar profile of expression to PPARg. Like PPARg, cyclin D2 is expressed in granulosa cells of developing follicles and downregulated within 4 h of the LH surge, but only in follicles that responded to the gonadotropin surge ). There are conflicting reports of how activation of PPARg affects cyclin D2. In human leukemic cells, activation of PPARg resulted in a decline in mRNA and protein for cyclin D2 (Laurora et al. 2003) . However, administration of troglitazone, a PPARg agonist, to cultured rat granulosa cells had no effect on cyclin D2 (Lovekamp-Swan & Chaffin 2005) . Froment et al. (2003) reported that treating granulosa cells from sheep with a PPARg agonist decreased granulosa cell proliferation. More work investigating the role of PPARg in granulosa cell-cycle progression is needed to address the apparent paradox of PPARg inhibiting cell proliferation yet being expressed at a high level in developing granulosa cells.
Because the function of PPARg varies depending on cell type and experimental parameters, it is difficult to define a role for PPARg in the ovary by extrapolating from studies in other systems. The current study shows that the expression of PPARg is tightly regulated in the ovary, and that its expression appears to be the primary way this transcription factor is influenced by LH. The pattern of expression of PPARg and its ability to affect a number of cellular functions suggest that its role in the ovary may be dictated by its relationship to other factors during the ovarian cycle. Because of its ability to influence many cellular functions, more work is needed to define the role of PPARg in the ovary in order to clarify how it is regulated and what genes it regulates during the ovarian cycle. 
